{"id":"placebo-ellipta-inhaler","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL523299","moleculeType":"Small molecule","molecularWeight":"508.50"},"_dailymed":null,"aiSummary":"The Placebo ELLIPTA inhaler is a device used in clinical trials by GlaxoSmithKline to serve as a control in studies evaluating the efficacy and safety of active drugs. It does not contain any active pharmaceutical ingredients and is designed to mimic the appearance and feel of the actual ELLIPTA inhaler. Since it is a placebo, it has no therapeutic effect and is not intended for use outside of clinical trials. The device is important for maintaining the integrity of blinded studies, ensuring that participants and researchers cannot distinguish between the placebo and the active treatment. No FDA label exists for this product, as it is not marketed for general use.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a placebo device designed to match the physical appearance, handling, and user experience of the active ELLIPTA inhaler without containing any therapeutic agent. It is used in randomized controlled trials to provide a blinded comparator arm, allowing researchers to isolate the true pharmacological effects of active medications from placebo response and device-related effects.","oneSentence":"The Placebo ELLIPTA inhaler delivers no active pharmaceutical ingredient, serving as an inert control device in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:39.527Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":0,"launchDate":"N/A","annualCostUS":0,"currentRevenue":0,"patientPopulation":"Clinical trial participants","peakSalesEstimate":0},"indications":{"approved":[{"name":"Clinical trial control comparator (not a therapeutic indication)"}]},"trialDetails":[{"nctId":"NCT07133880","phase":"PHASE4","title":"Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","status":"RECRUITING","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2023-12-05","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":72},{"nctId":"NCT02889809","phase":"PHASE4","title":"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Asthma","enrollment":477},{"nctId":"NCT04813354","phase":"PHASE4","title":"A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-04-14","conditions":"Asthma","enrollment":114},{"nctId":"NCT02522299","phase":"PHASE2","title":"A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-11-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03345407","phase":"PHASE2","title":"Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-11-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":943},{"nctId":"NCT04536675","phase":"PHASE3","title":"Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-04-01","conditions":"Chronic Obstructive Pulmonary Disease, Non Small Cell Lung Cancer","enrollment":204},{"nctId":"NCT03478657","phase":"PHASE4","title":"An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-18","conditions":"Asthma","enrollment":222},{"nctId":"NCT04750603","phase":"PHASE4","title":"Effect of Fluticasone Furoate/Vilanterol on EIA in Adolescents","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2018-12-01","conditions":"Asthma in Children","enrollment":92},{"nctId":"NCT03012061","phase":"PHASE2","title":"Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-25","conditions":"Asthma","enrollment":425},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT02991859","phase":"PHASE2","title":"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-09","conditions":"Asthma","enrollment":56},{"nctId":"NCT03611699","phase":"PHASE4","title":"Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients","status":"COMPLETED","sponsor":"Gary L. Pierce","startDate":"2019-01-24","conditions":"COPD","enrollment":15},{"nctId":"NCT03227445","phase":"PHASE4","title":"Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":240},{"nctId":"NCT02483975","phase":"PHASE3","title":"Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-09","conditions":"Asthma","enrollment":111},{"nctId":"NCT03034915","phase":"PHASE4","title":"A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2696},{"nctId":"NCT02982187","phase":"PHASE4","title":"A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":160},{"nctId":"NCT02730351","phase":"PHASE4","title":"Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-25","conditions":"Asthma","enrollment":75},{"nctId":"NCT02794480","phase":"PHASE4","title":"Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-22","conditions":"Asthma","enrollment":324},{"nctId":"NCT03175926","phase":"NA","title":"Description of the Ability to Learn How to Handle Inhaler Devices in Asthma","status":"WITHDRAWN","sponsor":"University Hospital, Bordeaux","startDate":"2017-12-01","conditions":"Asthma","enrollment":""},{"nctId":"NCT02786927","phase":"PHASE4","title":"Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-21","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":214},{"nctId":"NCT03315000","phase":"PHASE4","title":"Effect of Vilanterol on Methacholine Challenge Results","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2017-10-13","conditions":"Asthma","enrollment":17},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT02596009","phase":"PHASE4","title":"Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-12-16","conditions":"Pulmonary Disease, Chronic Obstructive (COPD)","enrollment":97},{"nctId":"NCT02487498","phase":"PHASE3","title":"Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-27","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":355},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT02487446","phase":"PHASE3","title":"Efficacy and Safety Study of QVA149 in COPD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-07-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":357},{"nctId":"NCT02502734","phase":"PHASE3","title":"Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-09-07","conditions":"Asthma","enrollment":60},{"nctId":"NCT02586493","phase":"PHASE4","title":"Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":278},{"nctId":"NCT02586506","phase":"PHASE4","title":"Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-01","conditions":"Asthma","enrollment":259},{"nctId":"NCT02184624","phase":"PHASE4","title":"Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":569},{"nctId":"NCT02691325","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22},{"nctId":"NCT02972905","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":36},{"nctId":"NCT02731846","phase":"PHASE3","title":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT02135718","phase":"","title":"ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06","conditions":"Asthma","enrollment":288},{"nctId":"NCT02195284","phase":"PHASE4","title":"To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-11","conditions":"Asthma","enrollment":162},{"nctId":"NCT01868009","phase":"PHASE3","title":"DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":287}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo ELLIPTA inhaler","genericName":"Placebo ELLIPTA inhaler","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"N/A","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}